JTV-161
Pulmonary arterial hypertension
Phase1Active
Key Facts
About Akros Pharma
Akros Pharma is a clinical-stage biotechnology company serving as the US development arm of Shionogi. Its pipeline consists of seven small molecule drug candidates, primarily in Phase 1 and Phase 2 trials, targeting autoimmune diseases, type 2 diabetes, chronic heart failure, neurodegenerative diseases, pulmonary arterial hypertension, and peripheral artery disease. The company leverages Shionogi's discovery engine and is led by a management team with deep expertise in clinical development, regulatory affairs, and intellectual property. As a private, subsidiary entity, its financial position and strategic direction are intrinsically linked to its parent company.
View full company profileTherapeutic Areas
Other Pulmonary arterial hypertension Drugs
| Drug | Company | Phase |
|---|---|---|
| Tadliq® (Tadalafil Oral Suspension) | CMP Pharma | Approved |
| PROPHET | Occlutech | Pilot |
| Soft Mist Inhaler for PAH (with unnamed Pharma Partner) | Resyca | Not Disclosed |
| LTSE-2578 | Structure Therapeutics | Phase 1 |
| Tyvaso DPI® | MannKind Corp | Approved |
| F230 | Gyre Therapeutics | Not Specified |